The findings from our study, therefore, consider the temporizing effect of Caplacizumab on platelet count alongside that of PEx, generating revised pooled evidence on the safety of the supplementation of the anti‐von Willebrand factor (VWF) therapy in TTP. Here, VWF is linked to thrombotic thrombocytopenic purpura.